Mediwound Ltd (MDWD) Stock Analysis
Verdict: WATCH (do not buy)
Solvency risk from a $20M annual burn vs $5M cash balance overrides pipeline potential until a non-dilutive financing event is secured.
Investment score: 46/100
Analysis as of
Is Mediwound Ltd stock worth reviewing? The TradeMates thesis
Avoid pending capital raise. Negative cash flow and massive revenue miss outweigh analyst optimism.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 25/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 60/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Mediwound Ltd opportunities and risks
What speaks for MDWD
- BARDA Contract Expansion
What speaks against MDWD
- Imminent Dilution Risk
Peers and competitors
- TEVA.TA
- SLGL
- CAVG
- INCR.TA
- REKA.TA
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MDWD | n/a | 10.4x | n/a | 19.6% | -180.3% | -16.2% |
| SLGL | n/a | 10.8x | n/a | 100.0% | -5.7% | 0.0% |
| CAVG | 12916.0x | 33.8x | 313.5x | 99.4% | 10.2% | 0.0% |
| Peer median | 6361.7x | 22.3x | 110.0x | 99.7% | 2.3% | 0.0% |
Frequently asked questions about Mediwound Ltd (MDWD)
Is MDWD stock a good investment?
The TradeMates model rates Mediwound Ltd as WATCH (do not buy) with an investment score of 46/100. Avoid pending capital raise. Negative cash flow and massive revenue miss outweigh analyst optimism. This is algorithmic model output, not personal investment advice.
Is MDWD stock a buy?
The TradeMates model verdict for MDWD is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.